目录产品 » TRAIL/TNFRSF10, His, Mouse
Manual
SDS
COAs

TRAIL/TNFRSF10, His, Mouse

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents.
￥2400
Z06391-100

产品简介
Species Mouse
Protein Construction
His TRAIL/TNFRSF10 (Pro118-Asn291)_x000D_
Accession # P50592
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Human TRAIL R1, hFc Tag captured on CM5 Chip via Protein A can bind TRAIL/TNFRSF10, His, Mouse, His Tag in SPR assay (Biacore T200). Test result was comparable to standard batch.
Expression System E.coli
Theoretical Molecular Weight 30.6 kDa
Apparent Molecular Weight The protein has a predicted MW of 30.6 kDa same as Bis-Tris PAGE result.
Formulation Supplied as 0.22μm filtered solution in 0.1M Glycine, 150mM NaCl, 10% Glycerol (pH 3.0).
Concentration Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford.
Storage & Stability This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents.
Synonyms Apo-2L; TRAIL; CD253; TNFSF10; Apo-2 ligand; APO2L; TL2
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.